Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?

Affiliations

¹ From the Department of Health Sciences (M.P.S.), Biostatistics Unit, University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.P.S.), Genoa, Italy; Queen Square Multiple Sclerosis Centre (C.T.), Department of Neuroinflammation, UCL Institute of Neurology, University College London, UK; Multiple Sclerosis Centre of Catalonia (C.T.), Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; UCL Queen Square Institute of Neurology (F.B.), and Centre for Medical Image Computing (F.B.), Department of Medical Physics and Biomedical Engineering, University College London, UK; and Radiology & Nuclear Medicine (F.B.), VU University Medical Centre, Amsterdam, the Netherlands. mariapia.sormani@unige.it.
² From the Department of Health Sciences (M.P.S.), Biostatistics Unit, University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.P.S.), Genoa, Italy; Queen Square Multiple Sclerosis Centre (C.T.), Department of Neuroinflammation, UCL Institute of Neurology, University College London, UK; Multiple Sclerosis Centre of Catalonia (C.T.), Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; UCL Queen Square Institute of Neurology (F.B.), and Centre for Medical Image Computing (F.B.), Department of Medical Physics and Biomedical Engineering, University College London, UK; and Radiology & Nuclear Medicine (F.B.), VU University Medical Centre, Amsterdam, the Netherlands.

Editorial

Maria Pia Sormani et al. Neurology. 2021.

. 2021 Jan 26;96(4):141-142.

doi: 10.1212/WNL.0000000000011312. Epub 2020 Dec 2.

¹ From the Department of Health Sciences (M.P.S.), Biostatistics Unit, University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.P.S.), Genoa, Italy; Queen Square Multiple Sclerosis Centre (C.T.), Department of Neuroinflammation, UCL Institute of Neurology, University College London, UK; Multiple Sclerosis Centre of Catalonia (C.T.), Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; UCL Queen Square Institute of Neurology (F.B.), and Centre for Medical Image Computing (F.B.), Department of Medical Physics and Biomedical Engineering, University College London, UK; and Radiology & Nuclear Medicine (F.B.), VU University Medical Centre, Amsterdam, the Netherlands. mariapia.sormani@unige.it.
² From the Department of Health Sciences (M.P.S.), Biostatistics Unit, University of Genoa; Ospedale Policlinico San Martino-IRCCS (M.P.S.), Genoa, Italy; Queen Square Multiple Sclerosis Centre (C.T.), Department of Neuroinflammation, UCL Institute of Neurology, University College London, UK; Multiple Sclerosis Centre of Catalonia (C.T.), Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; UCL Queen Square Institute of Neurology (F.B.), and Centre for Medical Image Computing (F.B.), Department of Medical Physics and Biomedical Engineering, University College London, UK; and Radiology & Nuclear Medicine (F.B.), VU University Medical Centre, Amsterdam, the Netherlands.

No abstract available

Comment on

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Naismith RT, Bermel RA, Coffey CS, Goodman AD, Fedler J, Kearney M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey J, Klingner E, Fox RJ; SPRINT-MS investigators. Naismith RT, et al. Neurology. 2021 Jan 26;96(4):e491-e500. doi: 10.1212/WNL.0000000000011314. Epub 2020 Dec 2. Neurology. 2021. PMID: 33268562 Free PMC article. Clinical Trial.